Malaria kills ∼600,000 people annually despite recently deployed vaccines. The parasite’s blood-stage invasion of erythrocytes, driven by the essential, non-redundant interaction between Plasmodium falciparum RH5 and erythrocyte basigin, remains a leading therapeutic target. Here, we designed de novo mini-proteins (“mi...
Jason Hsiao, Melina Shamshoum, Abhiram Chalamalasetty et al.· bioRxiv· 0 citations
COVID-19 highlighted the need for antivirals that can be rapidly deployed against both current and future coronavirus threats. CMX990 is a clinical stage coronavirus main protease (Mpro) inhibitor bearing a unique trifluoromethoxymethyl ketone warhead. Here, we broadly evaluate its pan-coronavirus target engagement, an...
N. G. R. Dayan Elshan, Karen C. Wolff, L. Riva et al.· bioRxiv· 0 citations
It is demonstrated that hotspot-guided design strategy, previously applied to proteins and d-peptides, can be effectively extended to l-peptide scaffolds, enabling the development of functional HA inhibitors informed by key residues at antigen–antibody interfaces.
R. U. Kadam, J. Juraszek, D. Branduardi et al.· ACS Medicinal Chemistry Lett...· 0 citations
The structural basis by which specific mutations enhance cross‐variant recognition of SARS‐CoV‐2 is defined, highlighting the underappreciated breadth encoded within the naïve B‐cell repertoire and providing a conceptual framework for engineering and eliciting antibody responses resilient to future antigenic drift.
Huibin Lv, Ziqi Feng, Q. Teo et al.· Advancement of science· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
